Ben Yi Tew1, Christophe Legendre2, Mark A Schroeder3, Tim Triche4, Gerald C Gooden1, Yizhou Huang4, Loren Butry5, Daniel J Ma3, Kyle Johnson2, Rae Anne Martinez2, Mariaelena Pierobon6, Emanuel F Petricoin6, Joyce O'shaughnessy7, Cindy Osborne7, Coya Tapia8, David N Buckley1, Jennifer Glen9, Mark Bernstein10, Jann N Sarkaria3, Steven A Toms5,10, Bodour Salhia1,2,11. 1. Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 2. Translational Genomics Institute (TGEN), Phoenix, Arizona, USA. 3. Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA. 4. Center of Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA. 5. Geisinger Medical Center, Danville, Pennsylvania, USA. 6. Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, Virginia, USA. 7. Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, Texas, USA. 8. Department of Molecular Pathology, The MD Anderson Cancer Center, Houston, Texas, USA. 9. University Health Network, Toronto, Ontario, Canada. 10. Lifespan, Providence, RI. 11. Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Abstract
BACKGROUND: The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. METHODS: We established 39 CM patient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patient tumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. RESULTS: PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patient tumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patient donor tumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. CONCLUSIONS: We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
BACKGROUND: The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. METHODS: We established 39 CMpatient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patienttumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. RESULTS: PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patienttumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patientdonortumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. CONCLUSIONS: We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
Authors: Yoko S DeRose; Guoying Wang; Yi-Chun Lin; Philip S Bernard; Saundra S Buys; Mark T W Ebbert; Rachel Factor; Cindy Matsen; Brett A Milash; Edward Nelson; Leigh Neumayer; R Lor Randall; Inge J Stijleman; Bryan E Welm; Alana L Welm Journal: Nat Med Date: 2011-10-23 Impact factor: 53.440
Authors: Eun Sung Park; Sun Jin Kim; Seung Wook Kim; Se-Lyun Yoon; Sun-Hee Leem; Sang-Bae Kim; Soo Mi Kim; Yun-Yong Park; Jae-Ho Cheong; Hyun Goo Woo; Gordon B Mills; Isaiah J Fidler; Ju-Seog Lee Journal: Proc Natl Acad Sci U S A Date: 2011-10-10 Impact factor: 11.205
Authors: Stephen K Chia; Vivien H Bramwell; Dongsheng Tu; Lois E Shepherd; Shan Jiang; Tammi Vickery; Elaine Mardis; Samuel Leung; Karen Ung; Kathleen I Pritchard; Joel S Parker; Philip S Bernard; Charles M Perou; Matthew J Ellis; Torsten O Nielsen Journal: Clin Cancer Res Date: 2012-06-18 Impact factor: 12.531
Authors: Hye Won Lee; Jung-Il Lee; Se Jeong Lee; Hyun Jung Cho; Hye Jin Song; Da Eun Jeong; Yun Jee Seo; Sang Shin; Je-Gun Joung; Yong-Jun Kwon; Yoon-La Choi; Woong-Yang Park; Hyun Moo Lee; Ho Jun Seol; Young Mog Shim; Kyeung Min Joo; Do-Hyun Nam Journal: Clin Cancer Res Date: 2014-12-30 Impact factor: 12.531
Authors: Anat Klein; Orit Sagi-Assif; Tsipi Meshel; Alona Telerman; Sivan Izraely; Shlomit Ben-Menachem; Jagadeesh Bayry; Diego M Marzese; Shuichi Ohe; Dave S B Hoon; Neta Erez; Isaac P Witz Journal: Oncotarget Date: 2017-05-09
Authors: Elizabeth Stewart; Sara M Federico; Xiang Chen; Anang A Shelat; Cori Bradley; Brittney Gordon; Asa Karlstrom; Nathaniel R Twarog; Michael R Clay; Armita Bahrami; Burgess B Freeman; Beisi Xu; Xin Zhou; Jianrong Wu; Victoria Honnell; Monica Ocarz; Kaley Blankenship; Jason Dapper; Elaine R Mardis; Richard K Wilson; James Downing; Jinghui Zhang; John Easton; Alberto Pappo; Michael A Dyer Journal: Nature Date: 2017-08-30 Impact factor: 49.962
Authors: Ben Yi Tew; Christophe Legendre; Gerald C Gooden; Kyle N Johnson; Rae Anne Martinez; Jeff Kiefer; Mark Bernstein; Jennifer Glen; Loren Butry; Aleksander Hinek; Steven A Toms; Bodour Salhia Journal: Oncogene Date: 2019-01-30 Impact factor: 9.867
Authors: Claudia C Faria; Rita Cascão; Carlos Custódia; Eunice Paisana; Tânia Carvalho; Pedro Pereira; Rafael Roque; José Pimentel; José Miguéns; Isidro Cortes-Ciriano; João T Barata Journal: Cell Rep Med Date: 2022-05-03
Authors: Amal Thomas; Teng Teng; Remi Klotz; Sung Min Han; Oihana Iriondo; Lin Li; Sara Restrepo-Vassalli; Alan Wang; Negeen Izadian; Matthew MacKay; Byoung-San Moon; Kevin J Liu; Sathish Kumar Ganesan; Grace Lee; Diane S Kang; Charlotte S Walmsley; Christopher Pinto; Michael F Press; Wange Lu; Janice Lu; Dejan Juric; Aditya Bardia; James Hicks; Bodour Salhia; Frank Attenello; Andrew D Smith; Min Yu Journal: Cancer Discov Date: 2019-10-10 Impact factor: 38.272
Authors: Anna C H Hoge; Michal Getz; Anat Zimmer; Minjeong Ko; Linoy Raz; Rameen Beroukhim; Todd R Golub; Gavin Ha; Uri Ben-David Journal: NPJ Precis Oncol Date: 2022-04-28
Authors: Yongheng Wang; Yuhang Jiang; Dengshuai Wei; Priya Singh; Yingjie Yu; Teresa Lee; Lingpu Zhang; Hanna K Mandl; Alexandra S Piotrowski-Daspit; Xinyuan Chen; Fan Li; Xing Li; Yiyu Cheng; Alexander Josowitz; Fan Yang; Yao Zhao; Fuyi Wang; Zhenwen Zhao; Anita Huttner; Ranjit S Bindra; Haihua Xiao; W Mark Saltzman Journal: Nat Biomed Eng Date: 2021-05-27 Impact factor: 25.671